Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

Amy D. Shapiro, K. John Pasi, Margareth C. Ozelo, Roshni Kulkarni, Christopher Barnowski, Bent Winding, Johan Szamosi, Stefan Lethagen

ARTIGO

Inglês

In the phase 3 B-LONG study (NCT01027364), prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) every 7 to >14 days was associated with low annualized bleed rates (ABRs) in males aged >= 12 years with severe hemophilia B. The long-term safety and efficacy of rFIXFc prophylaxis was...

Fechado

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

Amy D. Shapiro, K. John Pasi, Margareth C. Ozelo, Roshni Kulkarni, Christopher Barnowski, Bent Winding, Johan Szamosi, Stefan Lethagen


										

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

Amy D. Shapiro, K. John Pasi, Margareth C. Ozelo, Roshni Kulkarni, Christopher Barnowski, Bent Winding, Johan Szamosi, Stefan Lethagen

    Fontes

    Research and practice in thrombosis and haemostasis

    Vol. 3, no. 1 (Jan., 2019), p. 109-113